Rain Therapeutics Announces Patient Referral Partnership for the Planned MDM2-Amplified Phase 2 Basket Trial of RAIN-32

About this update from Rain Enhancement Technologies Holdco, Inc.

[{"type":"text","content":"Clinical trial for MDM2-amplified cancers expected to commence in second half of 2021\nNEWARK, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”), a clinical-stage company developing precision oncology therapeutics, today announced a patient referral partnership with Caris Life Sciences (“Caris”). Under the terms of the partnership, Caris will provide patient referral services using their molecular intelligence (MI) trials platform for Rain’s planned Phase 2 MDM2-amplified tumor-agnostic basket trial for RAIN-32, an oral MDM2 inhibitor in patients with certain solid tumors with pre-specified MDM2 amplification levels and wild type p53. “We are thrilled to partner with Caris, a company that shares our precision oncology mission, to identify patients for our tumor agnostic, MDM2-amplified basket trial strategy,” said Robert Doebele, M.D., Ph.D., co-founder, president and chief scientific officer of Rain. “Caris’ whole exome and whole transcriptome tumor sequencing assays will be critical for enrollment for the Phase 2 study, which is expected to commence in the second half of 2021.” “Caris puts the patient at the center of everything we do, and we are pleased to partner with Rain on this novel tissue-agnostic clinical study,” said Brian Lamon, Ph.D., Chief Business Officer, Head of BioPharma Business Development for Caris. “As the pioneer and industry leader in molecular profiling, this partnership builds upon our mission to save and extend patients’ lives through the most comprehensive molecular and artificial intelligence available in the industry.” About RAIN-32RAIN-32 (milademetan, formerly known as DS-3032), is a small molecule, oral inhibitor of mouse double minute 2 (MDM2), which is oncogenic in numerous cancers. Rain in-licensed RAIN-32 in September 2020 based on the results of a Phase 1 clinical trial, which demonstrated meaningful antitumor activity in an MDM2-amplified subtype of liposarcoma (LPS) and other solid tumors. This trial also validated a rationally-designed dosing schedule that has been shown to mitigate safety concerns and widen the therapeutic window of MDM2 inhibition, unlocking the potential for RAIN-32 in a broad range of MDM2- dependent cancers. Based on these data, we anticipate commencing a pivotal Phase 3 trial in LPS in the second half of 2021, a Phase 2 tumor-agnostic basket ...

More updates from Rain Enhancement Technologies Holdco, Inc.